Wide Ranks

AVBP

ArriVent BioPharma, Inc.

29.11

Top Statistics
Market Cap 980 M Forward PE -9.94 Revenue Growth 0.00 %
Current Ratio 25.50 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 298 M Total Cash Per Share 8.89 Total Debt 250000
Total Debt To Equity 0.0840 Current Ratio 25.50 Book Value Per Share -55.80
All Measures
Short Ratio 2421.00 % Message Board Id finmb_1671738162 Shares Short Prior Month 3 M
Return On Equity -0.3103 City Newtown Square Uuid dc868aa9-99a9-3d14-9b09-40806adb643e
Previous Close 28.74 First Trade Date Epoch Utc 1 B Book Value -55.80
Total Debt 250000 Volume 102087 Fifty Two Week Low 14.35
Total Cash Per Share 8.89 Shares Short Previous Month Date 1 B Target Median Price 38.50
Max Age 86400 Recommendation Mean 1.33 Sand P52 Week Change 0.3133
Target Mean Price 38.33 Net Income To Common -74885000 Short Percent Of Float 0.1482
Implied Shares Outstanding 33 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 200390 Average Volume10days 200390 Total Cash 298 M
Next Fiscal Year End 1 B Held Percent Insiders 0.0984 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 28.74
Target Low Price 36.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 28.43
Open 28.92 Free Cashflow -46733124 State PA
Dividend Yield 0.00 % Return On Assets -0.2122 Time Zone Short Name EST
Trailing Eps -2.61 Day Low 28.29 Address1 18 Campus Boulevard
Shares Outstanding 33 M Price Hint 2 Target High Price 41.00
Website https://www.arrivent.com 52 Week Change 0.4555 Average Volume 273492
Forward Eps -2.79 Recommendation Key strong_buy Compensation As Of Epoch Date 1 B
Quick Ratio 2474.90 % Is_sp_500 False Regular Market Day High 29.52
Profit Margins 0.00 % Debt To Equity 0.0840 Fifty Two Week High 36.37
Day High 29.52 Shares Short 3 M Regular Market Open 28.92
Industry Key biotechnology Earnings Growth 0.00 % Revenue Growth 0.00 %
Shares Percent Shares Out 0.1053 Operating Cashflow -68070000 Currency USD
Time Zone Full Name America/New_York Market Cap 980 M Is_nasdaq_100 False
Zip 19073 Quote Type EQUITY Industry Biotechnology
Long Name ArriVent BioPharma, Inc. Regular Market Day Low 28.29 Held Percent Institutions 0.7739
Current Price 29.11 Address2 Suite 100 Financial Currency USD
Current Ratio 25.50 Industry Disp Biotechnology Number Of Analyst Opinions 6
Country United States Float Shares 16 M Two Hundred Day Average 22.09
Enterprise Value 644 M Forward PE -9.94 Regular Market Volume 102087
Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States.

It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.

In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.

It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co.

, Ltd.

to develop and commercialize Furmonertinib.

The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.